PEDIATRICS Vol. 55 No. 5 May 1975, pp. 621-629
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Berman, B. A.
Right arrow Articles by Wall, L. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Berman, B. A.
Right arrow Articles by Wall, L. E.

Cromolyn Sodium in the Treatment of Children With Severe, Perennial Asthma

Bernard A. Berman M.D.1, Meryl M. Fenton M.D.1, Leonard S. Girsh M.D.1, Zack H. Haddad M.D.1, William A. Sellars M.D.1, Edward L. Strem M.D.1, Hugh C. Thompson M.D.1, and Lester E. Wall M.D.1

1 Allergy Clinic, Boston City Hospital and Tufts University School of Medicine, Boston; Wayne State University School of Medicine, Southfield, Michigan; Temple University Hospital and St. Christopher's Hospital for Children, Jenkentown, Pennsylvania; Los Angeles County— USC Medical Center, Beverly Hills, California; University of Texas Southwestern Medical School, Dallas; University of Minnesota Medical School, St. Paul; University of Arizona Medical Center, Tucson; and St. Louis University School of Medicine, St. Louis, Missouri

Cromolyn sodium is a recently introduced drug used in the prophylactic treatment of severe, perennial, bronchial asthma, particularly in the pediatric age group. In a multicenter trial, 276 chronic asthmatic patients of eight pediatric allergists entered a randomized, double-blind, placebo-controlled, crossover study lasting 12 weeks. Test compounds of cromolyn sodium or placebo were inhaled four times a day, and daily scores were kept of symptom severity as well as frequency of use of other medications. Patients had statistically significant lower average daily symptom scores when treated with cromolyn sodium as compared to treatment with placebo. A strong subjective preference for cromolyn sodium was expressed by 60% of those completing the trial, versus 9% for placebo. The patients' need for other symptomatic medications also dropped significantly during the cromolyn treatment period.

Submitted on April 3, 1974
Accepted on September 23, 1974